My HappyStock
Log in to track your learning progress.
Korean Companies
Find my preferred stocks →Compare companies across six criteria and explore businesses that fit your priorities.
328130
Lunit (328130)
Average score 4.8 F
Preference —
Lunit Inc. (trademark); logo hosted by Toolradar
Six company scores
Average score
Company growth8 / 10
Cancer-screening AI adoption and North American sales grow
Profitability1 / 10
Operating losses persist despite rising revenue
Financial stability4 / 10
Equity raised cash, but cash burn remains a risk
Economic moat7 / 10
Clinical validation and global distribution support its moat
Future outlook7 / 10
Medical AI demand and pharma partnerships offer upside
Valuation2 / 10
Losses and a rich sales multiple constrain valuation
Editorial scores are for education, not audited financial metrics or investment advice.
Revenue by business
- Cancer screening AI 93.6%
Lunit INSIGHT and Volpara screening solutions
- Oncology biomarker AI 6.4%
Lunit SCOPE and biomarker projects with drugmakers
Revenue by region
- Americas 72.9%
- Asia-Pacific 15.3%
- Europe and other 6.7%
- South Korea 5.1%
Key metrics
| Revenue CAGR (5 years) | 125% |
|---|---|
| Operating income CAGR (5 years) | - |
| Net income CAGR (5 years) | - |
| Operating margin (5-year avg.) | -289% |
| ROE (5-year avg.) | - |
| ROA (5-year avg.) | -44% |
| Beta (5 years) | - |
| MDD (5 years) | - |
| Payout ratio (5-year avg.) | 0% |
| P/E | - |
| Forward P/E | - |
| PEG | - |